PT1708679E - Formulação farmacêutica de vaporização compreendendo um hidrofluoralcano e uma ciclodextrina acilada - Google Patents

Formulação farmacêutica de vaporização compreendendo um hidrofluoralcano e uma ciclodextrina acilada Download PDF

Info

Publication number
PT1708679E
PT1708679E PT04798662T PT04798662T PT1708679E PT 1708679 E PT1708679 E PT 1708679E PT 04798662 T PT04798662 T PT 04798662T PT 04798662 T PT04798662 T PT 04798662T PT 1708679 E PT1708679 E PT 1708679E
Authority
PT
Portugal
Prior art keywords
fluor
hydro
alkane
spray formulation
pharmaceutical spray
Prior art date
Application number
PT04798662T
Other languages
English (en)
Portuguese (pt)
Inventor
Philippe Rogueda
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1708679E publication Critical patent/PT1708679E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT04798662T 2003-11-26 2004-11-24 Formulação farmacêutica de vaporização compreendendo um hidrofluoralcano e uma ciclodextrina acilada PT1708679E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds

Publications (1)

Publication Number Publication Date
PT1708679E true PT1708679E (pt) 2008-12-29

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04798662T PT1708679E (pt) 2003-11-26 2004-11-24 Formulação farmacêutica de vaporização compreendendo um hidrofluoralcano e uma ciclodextrina acilada

Country Status (23)

Country Link
US (1) US20070104652A1 (enExample)
EP (1) EP1708679B1 (enExample)
JP (1) JP4950666B2 (enExample)
KR (1) KR20060118509A (enExample)
CN (1) CN100592908C (enExample)
AT (1) ATE413868T1 (enExample)
AU (1) AU2004294775B2 (enExample)
BR (1) BRPI0416992A (enExample)
CA (1) CA2546441C (enExample)
CY (1) CY1108753T1 (enExample)
DE (1) DE602004017783D1 (enExample)
DK (1) DK1708679T3 (enExample)
ES (1) ES2314469T3 (enExample)
IL (1) IL175659A (enExample)
MX (1) MXPA06005643A (enExample)
NO (1) NO20062969L (enExample)
NZ (1) NZ547355A (enExample)
PL (1) PL1708679T3 (enExample)
PT (1) PT1708679E (enExample)
SE (1) SE0303179D0 (enExample)
SI (1) SI1708679T1 (enExample)
WO (1) WO2005053637A2 (enExample)
ZA (1) ZA200604330B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
JPWO2023127219A1 (enExample) * 2021-12-28 2023-07-06

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
AU2004294775B2 (en) 2007-12-20
ZA200604330B (en) 2007-11-28
HK1108390A1 (zh) 2008-05-09
US20070104652A1 (en) 2007-05-10
JP2007515401A (ja) 2007-06-14
NO20062969L (no) 2006-08-25
CY1108753T1 (el) 2014-04-09
JP4950666B2 (ja) 2012-06-13
SE0303179D0 (sv) 2003-11-26
WO2005053637A3 (en) 2007-06-28
CN101087600A (zh) 2007-12-12
CA2546441C (en) 2011-11-22
DE602004017783D1 (de) 2008-12-24
IL175659A (en) 2010-02-17
CA2546441A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
ES2314469T3 (es) 2009-03-16
ATE413868T1 (de) 2008-11-15
WO2005053637A2 (en) 2005-06-16
EP1708679B1 (en) 2008-11-12
CN100592908C (zh) 2010-03-03
IL175659A0 (en) 2006-09-05
SI1708679T1 (sl) 2009-04-30
BRPI0416992A (pt) 2007-02-06
PL1708679T3 (pl) 2009-04-30
NZ547355A (en) 2009-05-31
EP1708679A2 (en) 2006-10-11
AU2004294775A1 (en) 2005-06-16
MXPA06005643A (es) 2006-08-17
DK1708679T3 (da) 2009-02-16

Similar Documents

Publication Publication Date Title
AU2003236201A1 (en) Soluble formulations comprising monomeric insulin and acylated insulin
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2001058412A3 (de) Extrakte von rückständen aus der weinherstellung
WO2000056296A3 (en) Compositions for improving fertility
WO2005009356A3 (en) Method for the preparation of controlled release formulations
WO2004084950A3 (en) Cell targeting methods and compositions
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
EP1613663A4 (en) Crosslinked polysaccharide composition
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2004021968A3 (en) Solution for ungual application
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
WO2006069998A3 (de) Glycopyrrolat in kosmetischen zubereitungen
AU5218001A (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
AU2001262011A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
WO2006138735A3 (en) Gel compositions for topical administration
WO2003066597A3 (en) Guanidino compounds
WO2007019554A3 (en) Polysaccharides for delivery of active agents
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
IL175659A0 (en) Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
WO2005065717A3 (de) Flüssigformulierungen von antikörperkonjugaten
SE0300830D0 (sv) New formulations and use thereof